Main Street Financial Solutions’s UroGen Pharma URGN Stock Holding History

Main Street Financial Solutions’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$301K	Sell	8,190 -12,800	-61%	-$347K	0.02%	482
2026 Q1	$377K	Hold	20,990	–	–	0.03%	392
2025 Q4	$492K	Sell	20,990 -11,200	-35%	-$243K	0.04%	337
2025 Q3	$642K	Buy	32,190 +6,222	+24%	+$112K	0.04%	333
2025 Q2	$356K	Buy	25,968 +1,968	+8%	+$18.9K	0.03%	421
2025 Q1	$265K	Hold	24,000	–	–	0.02%	428
2024 Q4	$256K	Hold	24,000	–	–	0.03%	416
2024 Q3	$305K	Hold	24,000	–	–	0.03%	418
2024 Q2	$403K	Buy	+24,000	New	+$341K	0.04%	362

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Main Street Financial Solutions's URGN Position: Q2 2026 in Review

Main Street Financial Solutions reduced its UroGen Pharma (URGN) stake by 61% in Q2 2026, selling an estimated $347K and leaving 8,190 shares worth $301K. The position accounts for 0.02% of the portfolio, ranked #482.

Main Street Financial Solutions first reported a position in URGN in Q2 2024 and has held it in 9 quarters since. The position peaked at $642K in Q3 2025. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Main Street Financial Solutions held 8,190 shares of UroGen Pharma worth $301K as of Q2 2026.
Main Street Financial Solutions sold 12,800 UroGen Pharma shares in Q2 2026, an estimated $347K.
UroGen Pharma made up 0.02% of Main Street Financial Solutions's portfolio in Q2 2026, its #482 holding.
Main Street Financial Solutions first reported a position in UroGen Pharma in Q2 2024 and has held it in 9 quarters since.
Main Street Financial Solutions's UroGen Pharma position peaked at $642K in Q3 2025.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Main Street Financial Solutions's 13F filing for Q2 2026, filed 7 Aug 2026.